Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer

This article was originally published here

“We are encouraged by the European Commission’s and European Medicines Agency’s recognition of the benefit that zanidatamab can provide in the treatment of HER2-expressing gastric cancers as we

The post Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply